141 related articles for article (PubMed ID: 37974941)
1. Design and Biological Evaluation of Piperazine-Bearing Nitrobenzamide Hypoxia/GDEPT Prodrugs: The Discovery of CP-506.
Ashoorzadeh A; Mowday AM; Abbattista MR; Guise CP; Bull MR; Silva S; Patterson AV; Smaill JB
ACS Med Chem Lett; 2023 Nov; 14(11):1517-1523. PubMed ID: 37974941
[TBL] [Abstract][Full Text] [Related]
2. Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications.
Ashoorzadeh A; Mowday AM; Guise CP; Silva S; Bull MR; Abbattista MR; Copp JN; Williams EM; Ackerley DF; Patterson AV; Smaill JB
Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215297
[TBL] [Abstract][Full Text] [Related]
3. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
[TBL] [Abstract][Full Text] [Related]
4. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
[TBL] [Abstract][Full Text] [Related]
5. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
Jamieson SM; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR
Biochem Pharmacol; 2014 Mar; 88(1):36-45. PubMed ID: 24434189
[TBL] [Abstract][Full Text] [Related]
6. Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3.
Abbattista MR; Ashoorzadeh A; Guise CP; Mowday AM; Mittra R; Silva S; Hicks KO; Bull MR; Jackson-Patel V; Lin X; Prosser GA; Lambie NK; Dachs GU; Ackerley DF; Smaill JB; Patterson AV
Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959631
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
Abbattista MR; Jamieson SM; Gu Y; Nickel JE; Pullen SM; Patterson AV; Wilson WR; Guise CP
Cancer Biol Ther; 2015; 16(4):610-22. PubMed ID: 25869917
[TBL] [Abstract][Full Text] [Related]
8. The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy.
Green LK; Storey MA; Williams EM; Patterson AV; Smaill JB; Copp JN; Ackerley DF
Cancers (Basel); 2013 Aug; 5(3):985-97. PubMed ID: 24202330
[TBL] [Abstract][Full Text] [Related]
9. The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.
Foehrenbacher A; Patel K; Abbattista MR; Guise CP; Secomb TW; Wilson WR; Hicks KO
Front Oncol; 2013; 3():263. PubMed ID: 24109591
[TBL] [Abstract][Full Text] [Related]
10. Drug-DNA adducts as biomarkers for metabolic activation of the nitro-aromatic nitrogen mustard prodrug PR-104A.
Stornetta A; Deng KK; Danielli S; Liyanage HDS; Sturla SJ; Wilson WR; Gu Y
Biochem Pharmacol; 2018 Aug; 154():64-74. PubMed ID: 29630868
[TBL] [Abstract][Full Text] [Related]
11. Engineering the
Sharrock AV; McManaway SP; Rich MH; Mumm JS; Hermans IF; Tercel M; Pruijn FB; Ackerley DF
Front Pharmacol; 2021; 12():701456. PubMed ID: 34163368
[TBL] [Abstract][Full Text] [Related]
12. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.
Prosser GA; Copp JN; Mowday AM; Guise CP; Syddall SP; Williams EM; Horvat CN; Swe PM; Ashoorzadeh A; Denny WA; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2013 Apr; 85(8):1091-103. PubMed ID: 23399641
[TBL] [Abstract][Full Text] [Related]
13. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
Singleton RS; Guise CP; Ferry DM; Pullen SM; Dorie MJ; Brown JM; Patterson AV; Wilson WR
Cancer Res; 2009 May; 69(9):3884-91. PubMed ID: 19366798
[TBL] [Abstract][Full Text] [Related]
14. Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.
Hong CR; Mehta SY; Liyanage HDS; McManaway SP; Lee HH; Jaiswal JK; Bogle G; Tercel M; Pruijn FB; Wilson WR; Hicks KO
Cancer Chemother Pharmacol; 2021 Oct; 88(4):673-687. PubMed ID: 34245333
[TBL] [Abstract][Full Text] [Related]
15. Sulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104A.
Erzinger MM; Bovet C; Hecht KM; Senger S; Winiker P; Sobotzki N; Cristea S; Beerenwinkel N; Shay JW; Marra G; Wollscheid B; Sturla SJ
PLoS One; 2016; 11(3):e0150219. PubMed ID: 26950072
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy.
Chan-Hyams JVE; Copp JN; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2018 Dec; 158():192-200. PubMed ID: 30352235
[TBL] [Abstract][Full Text] [Related]
17. Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy.
Copp JN; Mowday AM; Williams EM; Guise CP; Ashoorzadeh A; Sharrock AV; Flanagan JU; Smaill JB; Patterson AV; Ackerley DF
Cell Chem Biol; 2017 Mar; 24(3):391-403. PubMed ID: 28262557
[TBL] [Abstract][Full Text] [Related]
18. AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.
Moradi Manesh D; El-Hoss J; Evans K; Richmond J; Toscan CE; Bracken LS; Hedrick A; Sutton R; Marshall GM; Wilson WR; Kurmasheva RT; Billups C; Houghton PJ; Smith MA; Carol H; Lock RB
Blood; 2015 Sep; 126(10):1193-202. PubMed ID: 26116659
[TBL] [Abstract][Full Text] [Related]
19. Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy.
Gu Y; Tingle MD; Wilson WR
J Pharmacol Exp Ther; 2011 Jun; 337(3):692-702. PubMed ID: 21427202
[TBL] [Abstract][Full Text] [Related]
20. Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.
Houghton PJ; Lock R; Carol H; Morton CL; Phelps D; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak AW; Gu Y; Wilson WR; Smith MA
Pediatr Blood Cancer; 2011 Sep; 57(3):443-53. PubMed ID: 21744473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]